Read more about MG Motor to drive in second electric model in India in next 2 years on Business Standard. MG Motor India can launch a new electric vehicle with a price tag below Rs 20 lakh mark in the country over the next two years, according to a top company official.The model would be the automaker s second electric vehicle in the country after the
MG partners with IIT Delhi for research on autonomous technology Updated Mar 16, 2021 | 19:08 IST
MG Motor India has partnered with IIT Delhi s Centre for Automotive Research and Tribology (CART) for research in the field of electric and autonomous vehicles. MG partners with IIT Delhi for research on autonomous technology | Photo Credit: Shutterstock
MG Motor India on Monday said it has joined hands with IIT Delhi s Centre for Automotive Research and Tribology (CART) for research in the field of electric and autonomous vehicles. The partnership through Foundation for Innovation and Technology Transfer (FITT), IIT Delhi aims at furthering the automaker s focus on CASE mobility (Connected Autonomous Shared Electric); through enabling supporting research for deployment of electric and autonomous vehicles in the urban landscape in the country, MG Motor India said in a statement. The company has already worked in the past with IIT Delhi on a year-l
Shilpa Medicare has received United States Food and Drug Administration (USFDA) s tentative approval for its abbreviated new drug application (ANDA), apremilast tablets, 10 mg, 20 mg, and 30 mg.
The ANDA was filed as First to File submission on NCE -1 date to seek eligibility for 180 days exclusivity.
Apremilast tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene, used in the treatment of psoriatic arthritis as recommended in the label approved by FDA.
According to IQVIA MAT Q2 2020 data, the US market for apremilast tablets, 10 mg, 20 mg, and 30 mg is approximately US $2.4 billion.
Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated markets.
Benchmark indices traded in a narrow range with modest losses in early afternoon trade. Resurgent worries about rising US bond yields hit global shares. The Nifty continued to hover around the 15,000 mark.
At 12:22 IST, the barometer index, the S&P BSE Sensex, was down 196.97 points or 0.39% at 50,649.20. The Nifty 50 index fell 70.45 points or 0.47% at 15,010.60.
In broader market, the S&P BSE Mid-Cap index was down 1.27% while the S&P BSE Small-Cap index was down 0.76%.
The market breadth turned negative. On the BSE, 1151 shares rose and 1590 shares fell. A total of 145 shares were unchanged.
COVID-19 Update:
Total COVID-19 confirmed cases worldwide stood at 115,597,805 with 25,69,011 deaths. India reported 176,319 active cases of COVID-19 infection and 157,548 deaths while 108,39,894 patients have been discharged, according to the data from the Ministry of Health and Family Welfare, Government of India.
Read more about Sensex drops 440 pts amid weak global cues, firm crude oil prices on Business Standard. As per the provisional closing data, the S&P BSE Sensex, tumbled 440.76 points or 0.87% at 50,405.20. The Nifty 50 index slumped 142.65 points or 0.95% at 14,938.60.